Latest Conference

The top 3 issues in treating bipolar disorder are...

Digital therapeutics may help improve negative symptoms associated with schizophrenia.

We've upgraded our phones and computers... is it time to upgrade our psychiatric medications?

Carmen Kosicek, MSN, PMHNP-BC, is ready to teach nurse practitioners and advanced providers in a fun, innovative way at Real Psychiatry in Scottsdale, AZ.

Are you attending Real Psychiatry this weekend?

DLX-001 is a novel neuroplastogen under development for the treatment of major depressive disorder. Learn more about the latest phase 1 data here.

Do lifestyle interventions really work in Alzheimer disease and what are the underlying mechanisms? Learn more in this ACNP 2024 Annual Meeting session!

In highlighting recent advances and fostering collaboration and networking, the ACNP Annual Meeting helps usher in 2025 with hope and positivity.

While complete abstinence is a good goal, what other clinically meaningful endpoints are there for patients with substance use disorders? Learn more in this ACNP 2024 Annual Meeting session!

Are you attending Real Psychiatry in January?

Here's why you should attend Real Psychiatry!

Posters from Psych Congress confirm the durability of long-term treatment with xanomeline/trospium (Cobenfy).

An associate professor of family medicine shares more on her presentations at the Family Medicine Experience 2024.

A board-certified family and sports medicine physician who works with individuals with eating disorders shares her thoughts on the Family Medicine Experience 2024.

The 2024 American Society of Clinical Psychopharmacology Annual Meeting brought together researchers and clinicians to engage in discussion, education, and dissemination of research findings and new methodologies.

Additionally, 27% of US adults have reported they have a disability across a spectrum of areas.

Recent research found approximately 60 documented cases of suicidal ideation and 7 suicide attempts associated with semaglutide use in patients.

Cannabis withdrawal syndrome impacts approximately half of those who use it regularly. How can you help patients cease cannabis use?

Check out the latest results from the phase 3 CONNEX-X study.

In this Special Report, get the latest from the American Psychiatric Association Annual Meeting!

Experts shared the study results in a poster presentation at the 2024 ASCP Annual Meeting.

Experts shared the study results in a poster presentation at the 2024 ASCP Annual Meeting.

Andrew Krystal, MD, and Wayne Drevets, MD, share their thoughts on the recent seltorexant data presented at the 2024 ASCP Annual Meeting.

How effective are these agents for AUD treatment? An expert shares highlights from his 2024 ASCP Annual Meeting Pharmaceutical Pipeline Update presentation.

A poster presented at the 2024 ASCP Annual Meeting discussed the results of a study on the treatment for depressive symptoms in this patient population.

A poster presented at the 2024 ASCP Annual Meeting discussed the results of a study on the efficacy and tolerability of the investigational schizophrenia treatment.

How effective is this treatment in real-world clinical settings? Experts explore this in a poster presented at the 2024 ASCP Annual Meeting.

A poster presented at the 2024 ASCP Annual Meeting discussed the results of a study analyzing the treatment’s safety and efficacy in this patient population.